Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Haemophilus B Conjugate Vaccine (National Institute of Allergy and Infectious Diseases)
- Development stage
- Approved
- Lead developer
- National Institute of Allergy and Infectious Diseases
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Haemophilus B Conjugate Vaccine is a biological product used to induce active immunity against invasive diseases caused by *Haemophilus influenzae* type b (Hib). The vaccine consists of the Hib capsular polysaccharide, polyribosylribitol phosphate (PRP), which is covalently linked (conjugated) to a carrier protein such as tetanus toxoid or meningococcal outer membrane protein. This conjugation converts the polysaccharide from a T-cell independent antigen to a T-cell dependent antigen, significantly enhancing its immunogenicity in infants and immunocompromised individuals. In the context of clinical research sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), such as the ACTG 5136 study, the Hib vaccine is frequently utilized as a standardized neoantigen or recall antigen to evaluate the functional recovery of the immune system in HIV-1 infected patients receiving intensified antiretroviral therapy (ART).
- Brand names
- ActHIBHiberixPedvaxHIB
- Other names
- Haemophilus influenzae type b conjugate vaccineHib conjugate vaccine
Beyond the preview
Go deeper on Haemophilus B Conjugate Vaccine (National Institute of Allergy and Infectious Diseases).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Haemophilus B Conjugate Vaccine (National Institute of Allergy and Infectious Diseases).